福安药业: 关于2025年中期现金分红预案的公告

Group 1 - The core point of the announcement is the proposed cash dividend plan for the first half of 2025, which aims to enhance shareholder returns and align with regulatory guidelines [1][2][3] - The company reported a net profit attributable to shareholders of 113,120,774.38 yuan for the first half of 2025, with cumulative undistributed profits of 900,948,123.05 yuan as of June 30, 2025 [1][2] - The proposed cash dividend is 0.20 yuan per 10 shares, totaling 23,794,247.64 yuan, and there will be no capital reserve conversion or bonus shares issued [1][2] Group 2 - The cash dividend proposal is in response to the government's call for increased dividend levels and frequency to enhance investor returns and confidence in the company's future [2][3] - The board of directors and the supervisory board have both approved the cash dividend plan, affirming its legality, compliance, and reasonableness based on the company's financial health and future prospects [3][4] - The company emphasizes that the implementation of this dividend plan will not adversely affect its liquidity or operational capabilities [2][4]